Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | HIV-Associated Lipodystrophy Therapeutics – Pipeline Assessment and Market Forecasts to 2017HIV-Associated Lipodystrophy Therapeutics Market Forecast to Demonstrate High Growth until 2017
By: Rajesh Gunnam Such high growth can be attributed to the Food and Drug Administration (FDA) approval of the first pharmacologic drug, Egrifta (tesamorelin) was approved in November 2010, at a premium price. The increasing awareness of HAL among HIV patients on highly active antiretroviral therapy (HAART) will drive future market growth, by causing an increase in the treatment seeking population. Until the approval of Egrifta, only off-label drugs were available for the treatment of HAL. Certain procedures such as injectable fillers and surgery were also available for the symptomatic relief from HAL. Currently Egrifta is the only approved drug in the US; however Theratechnologies applied for European Medicines Agency (EMEA) approval in Europe through its partner Ferrer International S.A in June, 2011. Egrifta will possess patent exclusivity until 2022 at the least. With the launch of Egrifta, the HAL therapeutics market witnessed the first pharmacologic drug for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy. Apart from Egrifta, which is awaiting regulatory approval in the European countrieas, there is no molecule in the late stage of the pipeline for HAL which is expected to influence the HAL therapeutics market. All the molecules are still in the early Phases of clinical development and are sponsored by either universities or institutes. The launch of Egrifta is expected to significantly affect the market as the treatment currently available for HAL was limited to the use of off-label drugs. The lack of specific, approved therapies previously acted as a barrier to the growth of the HAL therapeutics market. For Sample Pages, please click or add the below link to your browser: http://www.globaldata.com/ GlobalData’s analysis indicates that the current competition in the HAL therapeutics market is weak, as the market lacks therapies specifically approved by the FDA or the EMEA for the treatment of HAL. Egrifta, approved in November, 2010, is the only FDA approved drug for the treatment of HAL. Metformin, Avandia (rosiglitazone) Industry analysis specialist, GlobalData, has released its new report, “HIV-Associated Lipodystrophy Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information on the global HIV-associated lipodystrophy (HAL) therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global HAL therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global HAL sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/ Visit our report store: http://www.globaldata.com/ For more details contact: pressreleases@ North America: +1 646 395 5477 Europe: Asia Pacific: # # # GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number